The estimated Net Worth of Neil Solomons is at least $9.7 Million dollars as of 2 March 2022. Neil Solomons owns over 4,846 units of Aurinia Pharmaceuticals Inc stock worth over $593,923 and over the last 4 years he sold AUPH stock worth over $8,366,300. In addition, he makes $736,757 as Chief Marketing Officer at Aurinia Pharmaceuticals Inc.
Neil has made over 7 trades of the Aurinia Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 4,846 units of AUPH stock worth $58,200 on 2 March 2022.
The largest trade he's ever made was selling 250,000 units of Aurinia Pharmaceuticals Inc stock on 9 November 2021 worth over $7,507,500. On average, Neil trades about 77,121 units every 51 days since 2021. As of 2 March 2022 he still owns at least 90,953 units of Aurinia Pharmaceuticals Inc stock.
You can see the complete history of Neil Solomons stock trades at the bottom of the page.
Dr. Neil Solomons M.D. serves as Chief Marketing Officer of the Company. Dr. Neil Solomons co-founded privately-held Aurinia Pharmaceuticals in 2012. He is an experienced pharmaceutical physician with over 20 years of clinical development and medical affairs experience in both large pharma and biotech. He is a recognized expert in rare-disease drug development and is widely published in this field. Neil joined Aurinia from Vifor Pharma, formerly Aspreva Pharmaceuticals (Nasdaq:ASPV) where he held the position of Vice President, Research and Development, being the lead clinician in the development of CellCept® in rare diseases. Neil led the CellCept® Clinical Development teams of over 50 people that saw the completion, reporting, and publication of studies in pemphigus vulgaris and myasthenia gravis (both industry firsts), and the successful landmark lupus nephritis study called ALMS. He was responsible for all clinical development activities from Phases 1 to 3, as well as participating in the formulation of R&D strategy, portfolio management, and due diligence efforts. Prior to Vifor & Aspreva, Neil held a variety of positions at Roche in both Global Clinical Development and Medical Affairs in transplantation, virology, and auto-immune diseases. While at Roche, Dr. Solomons led a diverse team in the development and implementation of post-marketing studies for its transplantation (CellCept® and Zenapax®) and virology (Cytovene®) franchises. Neil qualified in medicine in 1991 receiving his MB BS (MD) at Guys Hospital Medical School, London. He subsequently worked as a physician in London UK, completing specialist training in anesthesia and intensive care. His research interests included sepsis and chronic pain.
As the Chief Marketing Officer of Aurinia Pharmaceuticals Inc, the total compensation of Neil Solomons at Aurinia Pharmaceuticals Inc is $736,757. There are 3 executives at Aurinia Pharmaceuticals Inc getting paid more, with Peter Greenleaf having the highest compensation of $1,678,600.
Neil's mailing address filed with the SEC is #1203-4464 MARKHAM STREET, , VICTORIA, A1, V8Z7X8.
Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden, and Michael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.
Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include: